Project overview

EBO-BOOST

We aim to address the ongoing threat of the Ebola Virus Disease by investigating optimal timing and safety of booster vaccinations for rapid deployment during outbreaks, and strengthening local epidemic preparedness.

Summary

The Ebola Virus Disease (EVD) remains a significant deadly threat with severe societal implications. There are currently two approved vaccines for Ebola prevention for which the duration of their protection remains uncertain. Given the periodic outbreaks in West and Central Africa, particularly in the Democratic Republic of the Congo (DRC), the need for revaccination arises. However, questions linger regarding the timing and method of revaccination, including the safety and efficacy of combining different vaccine types.

The aim of our study is to:

Facilitate the rapid deployment of vaccines during outbreaks.
Determine the efficacy and safety of combinations for booster shots and establishing clear guidelines for revaccination protocols.
Investigate factors for why certain individuals do not respond well to vaccines.
Strengthen local capacity for future epidemics through facilitating in-country testing infrastructure.

Funding

Coalition of Epidemic Preparedness Innovations (CEPI)
Merck Sharp & Dohme (MSD)
Directorate-General for Development Cooperation and Humanitarian Aid (DGD)

Project

Safety and immunogenicity of Ervebo® and Zabdeno® booster vaccines against Ebola Virus following previous vaccination with the Zabdeno/Mvabea® or Ervebo® vaccine schedules in DRC: a mix-and-match phase II RCT